Kala Pharmaceuticals Inc Cash Flow Conversion Efficiency
Kala Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has a cash flow conversion efficiency ratio of -0.651x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.56 Million) by net assets ($7.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kala Pharmaceuticals Inc (2013–2025)
Cash flow conversion efficiency of Kala Pharmaceuticals Inc from 2013 to 2025. This chart illustrates how Kala Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kala Pharmaceuticals Inc (KALA) stock price for real-time trading data and today's change.
Kala Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Kala Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kala Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see KALA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Strategic Financial
JK:APIC
|
-0.063x |
|
Springs Global Participações S.A.
SA:SGPS3
|
0.044x |
|
Bekasi Asri Pemula Tbk
JK:BAPA
|
-0.003x |
|
Petrotal Corp
LSE:PTAL
|
0.013x |
|
Fidelity Japanese Values PLC ORD
LSE:FJV
|
-0.002x |
|
PT Trimuda Nuansa Citra Tbk
JK:TNCA
|
-0.002x |
|
Knosys Ltd
AU:KNO
|
0.865x |
|
Omnia Metals Group Ltd
AU:OM1
|
-0.055x |
Annual Cash Flow Conversion Efficiency for Kala Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Kala Pharmaceuticals Inc from 2013 to 2025. Review Kala Pharmaceuticals Inc (KALA) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.00 Million | $-31.99 Million | -4.573x | -91.92% |
| 2024-12-31 | $12.33 Million | $-29.38 Million | -2.383x | +35.98% |
| 2023-12-31 | $7.50 Million | $-27.93 Million | -3.722x | +10.51% |
| 2022-12-31 | $18.97 Million | $-78.91 Million | -4.159x | +35.43% |
| 2021-12-31 | $16.80 Million | $-108.23 Million | -6.441x | -610.16% |
| 2020-12-31 | $100.00 Million | $-90.69 Million | -0.907x | +70.96% |
| 2019-12-31 | $29.69 Million | $-92.72 Million | -3.123x | -505.76% |
| 2018-12-31 | $104.99 Million | $-54.12 Million | -0.516x | -35.58% |
| 2017-12-31 | $89.68 Million | $-34.10 Million | -0.380x | -222.02% |
| 2016-12-31 | $-87.76 Million | $-27.35 Million | 0.312x | -88.04% |
| 2015-12-31 | $-5.79 Million | $-15.09 Million | 2.605x | +155.31% |
| 2014-12-31 | $3.26 Million | $-15.36 Million | -4.709x | +91.23% |
| 2013-12-31 | $202.00K | $-10.84 Million | -53.673x | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more